GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Short-Term Debt

Cambium Bio (ASX:CMB) Short-Term Debt : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Short-Term Debt?

Cambium Bio's Short-Term Debt for the quarter that ended in Dec. 2024 was A$0.00 Mil.

Cambium Bio's annual Short-Term Debt increased from Jun. 2022 (A$1.00 Mil) to Jun. 2023 (A$1.95 Mil) but then declined from Jun. 2023 (A$1.95 Mil) to Jun. 2024 (A$0.00 Mil).


Cambium Bio Short-Term Debt Historical Data

The historical data trend for Cambium Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Short-Term Debt Chart

Cambium Bio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 - 1.00 1.95 -

Cambium Bio Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 1.95 - - -

Cambium Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Cambium Bio Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Cambium Bio Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines